Hence, here we sought to explore the molecular mechanisms underlying SIRT3’s regulation of the fate of NSCs, and whether SIRT3 and its downstream targets would be good pharmacological targets to rescue neurogenic potential in aging and depression contexts. The gene discussed is SIRT3; the disease is depressive symptom measurement.